

AEM SAFETY - PERFORMANCE - VALUE

Investor Overview 2016

ENCISION



Encision Inc. Disclaimer Statement

The following information does not purport to be all-inclusive or to contain all the information that you may desire in investigating us. You should conduct and rely on your own evaluation of us, including the merits and risks involved, in making an investment decision with respect to our shares. This document and our periodic reports filed with the SEC contain certain forward-looking statements that involve risks and uncertainties with respect to our business and our industry. Our actual results could differ materially from those included in forward-looking statements. Factors that could contribute to these differences include those matters discussed in the Risk Factors sections of our periodic reports filed with the SEC. We assume no obligation to update such forward-looking statements or to update the reasons that actual results could differ materially from those anticipated in such forward-looking statements.

Company Background

- Founded in February 1991 under the name Electroscope, Inc
- Public Company in 1996
- Name changed to Encision Inc. in August 2000
- 47 Full Time Employees
- 29,000 square foot facility in Boulder, CO


in Boulder, CO

Mission is to save lives with AEM® Technology, to enhance surgical performance and to drive customer value.

Significant & Growing Market

- 750K laparoscopic cholecystectomies performed annually (U.S.)
- Total laparoscopic procedures (US) approximately 4 million*
- Disposable monopolar laparoscopic instrument potential market (disposables only - \$480 million)
- Current estimate 65% disposable remainder reusable
- Current Encision market share of disposable monopolar market 3.0%

Surgical Energy for Open and Laparoscopic Procedures



Surgical Energy comes in three primary modalities

Surgical Energy for Open and Laparoscopic Procedures



Open Procedure



Laparoscopic




Robotic

Surgical Energy For Laparoscopic Procedures


Monopolar Energy is the most common type of surgical energy and is found in almost 100% of Operating Rooms worldwide. Prolific in both Open and Laparoscopic surgical procedures, Monopolar provides the fastest cutting and coagulation performance of all the energy modalities.

But dangers are present with all surgical energy modalities. Along with Monopolar's outstanding performance in Cutting and Coagulation, the flow of high frequency monopolar energy through Laparoscopic Instruments creates potentially deadly patient complications from *Stray Energy*.



Stray Energy = Potential Thermal Injury

Stray Energy comes in two forms:



Energy arcs to unintended organs through intact instrument insulation



Energy arcs to unintended organs through a defect in the instrument's insulation

The most dangerous aspect of these injuries is that they happen outside the field of vision of the surgeon and go unnoticed until the patient arrives back at the emergency room in critical condition.

A laparoscopic stray energy burn occurs every 90 minutes in the USA

Instrumentation
Insulation-failure Rates

1 in 5 Reusables1 in 33 Disposables

Capacitive Coupling Frequency

Can occur anytime monopolar energy is used

Deadly Stray Energy

\$371 million in CMS Funding in 2015

\$30K+


per readmission

\$438K

per lawsuit Stray Energy Burns are not caused by surgical technique – they are a fundamental flaw in monopolar surgical energy

Encision is the *only* company to solve this problem through advanced **AEM®** Technology!


How AEM® Works



AEM® Value Positioning


Clinical Value: AEM® Technology alone saves patients' lives by eliminating stray energy burns during laparoscopy.

Economic Value: AEM® Technology alone reduces hospital liability by eliminating a source of surgical malpractice, reduces hospital risk of HAC/APL and subsequent CMS penalties, and reduces costly readmissions and associated unreimbursed expenses.




CMS aims to reduce patient complications with the new HAC Reduction Program

- The Hospital Acquired Condition (HAC) Reduction Program
 Penalizes 1% of CMS
 reimbursements, from the worst performing 25% of hospitals
- 2015-2017, hospitals with poor HAC scores will lose a combined \$1Billion in reimbursements



CMS aims to reduce patient complications with the new HAC Reduction Program

- Accidental Puncture &
 Lacerations (APLs) are the third
 largest part of the HAC score
- Half of all Laparoscopic APLs are from Stray Energy Burns to patients





Encision 2015 - Rebuilding to Win

Sales

New Product Introductions Delivering customer-centric products to market that get them excited about surgical performance and patient safety

Awareness and Demand Creation Getting the message out through conferences, social media, and surgical specialty targeting

Create, Train, and Equip a Global Sales Channel

Establishing a high performance sales team and full sales pipeline

Repositioning and Rebuilding Core Message

It's not the surgical technique — It's a fundamental weakness of monopolar energy

Leadership Transition and Culture Building

New Leadership Team driving new levels of Quality and Operational Excellence

2016 Marketing and Sales Strategy

Marketing

- Continue to drive our core mission that Encision saves lives with AEM® Technology while reducing patient complications and readmissions. 2016 focus on General and GYN Specialties.
- Back it up with strong clinical and economic value, compelling content, and new evidence –
 Leverage the CMS HAC Initiative to drive increasing awareness.
- Grow the demand for AEM® Technology with CE Safety Programs, HAC Reduction Education, and safety/performance enhancing product introductions.

Sales

- Refine and expand our worldwide Sales Channel.
- Support it with training, evidence, and technological expertise.
- Launch AEM® Technology into select OUS Markets.
- Drive new revenues and with cost effective AEM EndoShield® and other new products.
- Capitalize on strategic OEM and Partnership opportunities.



Encision Vision

Return to profitability by early 2016 then drive to 20% annual growth

New AEM® Product Introductions and Development

US & OUS Channel Expansion

Increased Customer Awareness

New CMS Reimbursement Policies



2016

2017

2018

Summary

- Encision's patented AEM® is the <u>only technology</u> that continuously monitors instruments during laparoscopic surgery to eliminate stray monopolar energy burns
- The timing is right for adoption and expansion
 - New clinical and economic value for Hospitals
 - HAC Reduction Initiative from CMS
 - Increasing awareness of the dangers of Stray Energy
 - New demand from hospital systems
 - New clinical evidence to support AEM® Adoption
- Poised for success in 2016!



